AnGes (4563) Fundamentals 2026 — Revenue Analysis | SniperIQ
AnGes (4563) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥19.0B, trading at ¥48.00 on the JPX. This SniperIQ fundamentals page covers AnGes's valuation, profitability (net margin -545.7%), revenue (¥874M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is AnGes's market cap?
AnGes (4563) has a market capitalization of approximately ¥19.0B, trading at ¥48.00 on the JPX. Market cap moves with the live share price.
What is AnGes's P/E ratio?
AnGes's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is AnGes?
AnGes runs a net profit margin of -545.7%, a gross margin of 38.1%, and an operating margin of -592.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does AnGes generate?
AnGes reported revenue of ¥874M for fiscal year 2025, with net income of -¥5.1B and earnings per share (EPS) of -14.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does AnGes pay a dividend?
AnGes does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is AnGes financially healthy?
AnGes carries a debt-to-equity ratio of 0.34x and a current ratio of 1.97x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is AnGes a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AnGes (4563) the key facts are: market cap ¥19.0B, revenue ¥874M, 52-week range 44-120. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track AnGes's full fundamentals live
Get AnGes's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.